Oral step-down therapy for infective endocarditis


Background: The standard of care for IE has been a prolonged course of IV antibiotics. Recent literature has suggested that oral antibiotics might be a safe and effective step-down therapy for IE.

Dr. Elizabeth Yoo, division of hospital medicine, Mount Sinai Health System, New York

Dr. Elizabeth Yoo

Study design: Systematic review.

Setting: Literature review in October 2019, with update in February 2020, consisting of 21 observational studies and 3 randomized controlled trials.

Synopsis: Three RCTs and 21 observational studies were reviewed, with a focus on the effectiveness of antibiotics administered orally for part of the therapeutic course for IE patients. Patients included in the study had left- or right-sided IE. Pathogens included viridians streptococci, staphylococci, and enterococci, with a minority of patients infected with methicillin-resistant Staphylococcus aureus. Treatment regimens included beta-lactams, linezolid, fluoroquinolones, trimethoprim-sulfamethoxazole, or clindamycin, with or without rifampin.

In studies wherein IV antibiotics alone were compared with IV antibiotics with oral step-down therapy, there was no difference in clinical cure rate. Those given oral step-down therapy had a statistically significant lower mortality rate than patients who received only IV therapy.

Limitations include inconclusive data regarding duration of IV lead-in therapy, with the variance before conversion to oral antibiotics amongst the studies ranging from 0 to 24 days. The limited number of patients with MRSA infections makes it difficult to draw conclusions regarding this particular pathogen.

Bottom line: Highly orally bioavailable antibiotics should be considered for patients with IE who have cleared bacteremia and achieved clinical stability with IV regimens.

Citation: Spellberg B et al. Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review. JAMA Intern Med. 2020;180(5):769-77. doi: 10.1001/jamainternmed.2020.0555.

Dr. Yoo is a hospitalist in the Division of Hospital Medicine, Mount Sinai Health System, New York.

Recommended Reading

Empagliflozin a winner in challenging arena of stabilized acute HF
The Hospitalist
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
The Hospitalist
Predicting cardiac shock mortality in the ICU
The Hospitalist
Optimizing perioperative cardiac risk assessment and management for noncardiac surgery
The Hospitalist
Bedside frailty assessment can determine when CPR will be nonbeneficial
The Hospitalist
SGLT2 inhibitor use tied to fewer atrial arrhythmias
The Hospitalist
No serious CV risks for elderly after Pfizer COVID-19 vaccine
The Hospitalist
Care via video teleconferencing can be as effective as in-person for some conditions
The Hospitalist
Apixaban outmatches rivaroxaban for VTE in study
The Hospitalist
New data on rare myocarditis after COVID-19 vaccination
The Hospitalist
   Comments ()